Naratriptan and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Naratriptan (naratriptan), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Ocrevus, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Weakness when taking Naratriptan. It is created by eHealthMe based on reports of 1,407 people who have side effects when taking Naratriptan from the FDA, and is updated regularly.

What is Naratriptan?

Naratriptan has active ingredients of naratriptan. It is often used in migraine. eHealthMe is studying from 1,481 Naratriptan users. Check the latest studies of Naratriptan.

What is Weakness?

Weakness is found to be associated with 3,640 drugs and 6,614 conditions by eHealthMe. Check the latest studies of Weakness.

On Aug, 03, 2026

1,407 people reported to have side effects when taking Naratriptan.
Among them, 44 people (3.13%) have Weakness.

Among these 44 people:

How long have people been on Naratriptan when they have Weakness? *

What is the gender of people who have Weakness when taking Naratriptan? *

female: 85.71 %
male: 14.29 %

What is the age of people who have Weakness when taking Naratriptan? *

What are other drugs people take besides Naratriptan? *

What are other side effects people have besides Weakness? *

Fatigue (feeling of tiredness): 23 people, 52.27%
Headache (pain in head): 22 people, 50.00%
Nausea (feeling of having an urge to vomit): 14 people, 31.82%
Nasopharyngitis (inflammation of the nasopharynx): 13 people, 29.55%
Cough: 12 people, 27.27%
Hypoaesthesia (reduced sense of touch or sensation): 11 people, 25.00%
Pain: 11 people, 25.00%
Influenza Like Illness: 10 people, 22.73%
Dizziness: 10 people, 22.73%
Listless (lack of interest, energy, or spirit): 9 people, 20.45%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 9 people, 20.45%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 6 people, 13.64%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 11.36%
Fabry's Disease (build up of a particular type of fat, called globotriaosylceramide, in the body's cells): 4 people, 9.09%
Fainting (loss of consciousness and postural tone): 3 people, 6.82%
Gait Disturbance: 3 people, 6.82%
Rhinitis (a medical term for irritation and inflammation of the mucous membrane inside the nose): 3 people, 6.82%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 3 people, 6.82%
Cough: 3 people, 6.82%
Dizziness: 3 people, 6.82%

* Approximation only. Some reports may have incomplete information.

Do you take Naratriptan and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Naratriptan:

Naratriptan (1,481 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Naratriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,640 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,614 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on naratriptan (the active ingredients of Naratriptan) and Naratriptan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.